# An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

> **NCT04711850** · — · TERMINATED · sponsor: **Hansa Biopharma AB** · enrollment: 18 (actual)

## Conditions studied

- Kidney Transplant Rejection

## Interventions

- **DRUG:** Imlifidase

## Key facts

- **NCT ID:** NCT04711850
- **Lead sponsor:** Hansa Biopharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-20
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** This is an internal decision based on prioritisations and no safety issues have been raised during the trial.
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04711850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04711850, "An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04711850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*